Home Tags HER2

Tag: HER2

General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial...

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

MI130004 Shows Positive in vivo Activity against HER2-Expressing Tumors

Positive results of MI130004, a novel antibody-drug conjugate combining trastuzumab via Cys residues through a non-hydrolysable linker, with PM050489, a molecule of marine origin,...

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

First Patient Dosed in Pivotal Phase II DESTINY-Gastric01 Study of DS-8201

A first patient has been enrolled in DESTINY-Gastric01 (NCT03329690), a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy...

Alteogen Expects to Initiate Phase I trial of novel HER2 targeting...

In late august, Korean-based Alteogen announced that it expect to initiate a phase I clinical trial for ALT-P7, a novel antibody-drug conjugate or ADC...

Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...

Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Study Shows Therapeutic Potential of an anti-HER2 single chain antibody–DM1 conjugates

In an attempt to develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, a team of researchers led by...

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...

DOWNLOAD